Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2206 in advanced hepatocellular carcinoma
NCT01239355Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2010
- Primary completion
- Feb 2013
- Countries
- 1
01
Overview
A Phase 2 trial of MK-2206 in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Started Dec 2010; status: terminated.
02
Drugs
MK-2206
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01239355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01239355.